ÂÜÀòÂÒÂ×

Pedro Lichtinger serves as the Chairman and CEO of Starton Therapeutics since March 2017, where strategic leadership has driven the company's growth in proprietary transdermal technology for cancer treatment. Previously, Lichtinger held roles as President and CEO at Asterias Biotherapeutics, where alliances were formed for innovative therapies, and at Optimer Pharmaceuticals, leading the successful market launch of Dificid. Significant contributions also include overseeing the Global Primary Care Business Unit at Pfizer, managing $23 billion in revenue, and spearheading initiatives in both animal health and human health sectors. Lichtinger's extensive experience in the pharmaceutical and biotechnology industries is supported by an MBA from The Wharton School and a BSC in Engineering from UNAM.